SB-3CT

Confirm delete?

SB-3CT

Zoom

Cat No: 16337

Biochemicals - Small Molecule Inhibitors

SB-3CT is a selective, mechanism-based inhibitor of the gelatinases, matrix metalloproteinase-2 (MMP-2) and MMP-9 (Kis = 28 and 400 nM, respectively).{26759,26757} First pass metabolism of SB-3CT in vivo produces a monohydroxylated metabolite that has...

This product can only be bought through Cayman Chemical. Please contact us.

Product Overview
Data
Downloads
About Cayman

Territorial Availability: Available through Bertin Technologies only in France

Synonyms:

2-[[(4-phenoxyphenyl)sulfonyl]methyl]-thiirane

Correlated keywords:

inhibitors cancers neurosciences inflammation vascular diseases protease inhibits inhibitions SB3CT SB 3CT gelatinases matrix metalloproteinase-2 metalloproteinase 2 MMP2 MMP MMP-2 9 MMP9 MMP-9 metabolism metabolites blood brains barriers central nervous systems CNS strokes injury pathologies pathology cardiovascular 329328-04-3

Product Overview:
SB-3CT is a selective, mechanism-based inhibitor of the gelatinases, matrix metalloproteinase-2 (MMP-2) and MMP-9 (Kis = 28 and 400 nM, respectively).{26759,26757} First pass metabolism of SB-3CT in vivo produces a monohydroxylated metabolite that has greater inhibitory activity (Kis = 6 and 160 nM for MMP-2 and MMP-9, respectively).{26757} Both SB-3CT and its active metabolite can cross the blood-brain barrier and have utility in diseases of the central nervous system, such as stroke and traumatic brain injury.{26757,26758} SB-3CT may have applications in other pathologies involving gelatinases, including cancer, cardiovascular diseases, and inflammation.{26760,26756}

Size	500 µg
Shipping	dry ice
CAS Number	292605-14-2
Molecular Formula	C₁₅H₁₄O₃S₂
SMILES	O=S(C(C=C1)=CC=C1OC2=CC=CC=C2)(CC3SC3)=O
Molecular Weight	306,4
Formulation	A crystalline solid
Purity	≥95%
Custom Code	2932.99
UNSPSC code	12352100

Technical File

MSDS

Click here to ask for your quote and get 15% off Cayman's products.

Cayman Chemical's mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.

Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.

Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.

Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.

Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009

Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.